We thank Professor Siriwardena and colleagues for their valuable comments on our manuscript.
1
It seems like we share the view that arranging a randomized controlled trial for
patients with colorectal cancer and synchronous liver metastases is hard, if not unfeasible.
We are happy to see that the authors highlight our algorithmic approach to patient
selection in devising a treatment plan. Finally, we agree with Professor Siriwardena
and colleagues, that treatment decisions in the future will be more influenced by
an in-depth knowledge of the biology of the primary cancer, and perhaps also the biology
of the metastases. Recent developments in spatial transcriptomics point towards a
more precision based medicine.To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to HPBAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
Reference
- A comparison of the simultaneous, liver-first, and colorectal-first strategies for surgical treatment of synchronous colorectal liver metastases at two major liver-surgery institutions in Sweden.HPB. 2022;
Article info
Publication history
Published online: March 18, 2023
Accepted:
March 10,
2023
Received:
March 3,
2023
Publication stage
In Press Corrected ProofIdentification
Copyright
© 2023 International Hepato-Pancreato-Biliary Association Inc. Published by Elsevier Ltd. All rights reserved.
